| Cemile Gunalp, | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-5000 | |
| Not Available |
| Full Name | Cemile Gunalp |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649730714 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D98759 (Maryland) | Primary |
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
The dietary supplement chitosan shows some promise in treating overweight and obesity but has not been shown conclusively to be an effective weight loss aid, according to a new systematic review of current evidence.
Nature News reports on last week's announcement of preliminary results from a large clinical trial testing the efficacy of GlaxoSmithKline's (GSK) RTS,S malaria vaccine, writing that while media coverage of the announcement touted it as a "big breakthrough in the long campaign to create a malaria vaccine," "several leading vaccine researchers, who are critical of the unusual decision to publish partial trial data, argue that the results raise questions about whether the RTS,S/AS01 candidate vaccine can actually win approval."
Hormone replacement therapy (HRT) is associated with an increased risk of stroke, especially ischaemic stroke, finds a review of trials published on bmj.com today.
Scientists have puzzled over just why organisms evolved aging as a strategy, and now there appears to be an answer. Allowing one individual to carry all the cellular damage inflicted over time, rather than dividing it between two organisms during reproduction, increases the chances that the individual's line will continue to reproduce for many generations to come, a new study indicates.
DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cemile Gunalp, 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-6423 | Cemile Gunalp, 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-5000 |
News Archive
The dietary supplement chitosan shows some promise in treating overweight and obesity but has not been shown conclusively to be an effective weight loss aid, according to a new systematic review of current evidence.
Nature News reports on last week's announcement of preliminary results from a large clinical trial testing the efficacy of GlaxoSmithKline's (GSK) RTS,S malaria vaccine, writing that while media coverage of the announcement touted it as a "big breakthrough in the long campaign to create a malaria vaccine," "several leading vaccine researchers, who are critical of the unusual decision to publish partial trial data, argue that the results raise questions about whether the RTS,S/AS01 candidate vaccine can actually win approval."
Hormone replacement therapy (HRT) is associated with an increased risk of stroke, especially ischaemic stroke, finds a review of trials published on bmj.com today.
Scientists have puzzled over just why organisms evolved aging as a strategy, and now there appears to be an answer. Allowing one individual to carry all the cellular damage inflicted over time, rather than dividing it between two organisms during reproduction, increases the chances that the individual's line will continue to reproduce for many generations to come, a new study indicates.
DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.
› Verified 8 days ago
Miss Elizabeth Unique Morris, MSN, WHNP-BC Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 330 N Howard St, Baltimore, MD 21201 Phone: 410-576-1414 | |
Christine E. O Connor, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 227 Saint Paul St, 6th Floor, Baltimore, MD 21202 Phone: 410-332-9002 Fax: 410-783-5880 | |
Amara Chinyere Unegbu-ogbonna, PA-C Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 345 St. Paul Place, Bunting Building - Department Of Ob/gyn, Baltimore, MD 21202 Phone: 410-332-9000 | |
Fateh Hraky Sr., Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3001 S Hanover St, Suite 301, Baltimore, MD 21225 Phone: 410-350-0800 | |
Joyce A Bonsu, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3449 Wilkens Ave Ste 305, Baltimore, MD 21229 Phone: 410-644-2582 Fax: 410-644-6232 | |
Fouad M Abbas, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2411 W Belvedere Ave, Suite 206, Baltimore, MD 21215 Phone: 410-601-9030 | |
Dr. Ginny M Merryman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6569 N Charles St, Suite 501, Baltimore, MD 21204 Phone: 410-938-8960 Fax: 410-583-9770 |